Buffi Boyd, MD
Urology · Savannah, GANPI 1902861917
Payments from drug & device makers
What this record shows
32 manufacturers reported payments, led by Intuitive Surgical at 52.9% of the total. Reporting peaked in 2020 at $3,274 and has fallen 88.2% since, to $385 in 2025.
Across 166 payments — averaging $36.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AbbVie$837
- Pfizer$240
- Astellas Pharma US Inc$236
- Sumitomo Pharma America, Inc.$228
- Medtronic$188
- plus $1K from 26 others
Across 26 payments — averaging $1847.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$19K
- Medtronic$15K
- OPKO Pharmaceuticals, LLC$12K
- Urovant Sciences Inc$1K
- Cepheid$209
What the payments were for
- Food & beverage$3,01250%
- Education$3,00450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $3,184 |
| AbbVie(2 entities) | 54 | $837 |
| Pfizer | 13 | $240 |
| Astellas Pharma US Inc | 14 | $236 |
| Sumitomo Pharma America, Inc. | 13 | $228 |
| Medtronic(2 entities) | 10 | $188 |
| Merck | 7 | $159 |
| Myovant Sciences Inc. | 1 | $114 |
| Endo Pharmaceuticals Inc. | 8 | $110 |
| Coloplast | 4 | $100 |
| Bayer | 5 | $72 |
| Boston Scientific | 4 | $65 |
| AstraZeneca | 3 | $49 |
| Amgen | 3 | $46 |
| Johnson & Johnson | 3 | $40 |
| Urogen Pharma, Inc. | 2 | $36 |
| Novartis | 2 | $35 |
| Davol Inc. | 1 | $31 |
| Rochester Medical Corporation | 1 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Calyxo, Inc. | 1 | $21 |
| Blue Earth Diagnostics | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| 180 Medical, Inc. | 1 | $17 |
| Urovant Sciences Inc | 1 | $15 |
| Neotract Inc. | 1 | $13 |
| Innovation Technologies Inc | 1 | $13 |
| Foundation Medicine, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 2 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,105
- ORGOVYX$114
How this compares
$6,016 in reported general payments places this provider in the 60th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 227 | $153,747 |
| MyrbetriqMirabegron | 135 | $92,345 |
| Methenamine Hippurate | 176 | $12,142 |
| TlandoTestosterone Undecanoate | 12 | $8,977 |
| ElmironPentosan Polysulfate Sodium | 14 | $7,239 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 266 | $3,526 |
| Tamsulosin Hcl | 341 | $3,499 |
| Trospium Chloride | 66 | $2,943 |
| Potassium Citrate ErPotassium Citrate | 28 | $2,680 |
| Trimethoprim | 58 | $2,188 |
| Desmopressin Acetate | 22 | $1,905 |
| NitrofurantoinNitrofurantoin Macrocrystal | 88 | $1,779 |
| Estradiol | 19 | $1,498 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $1,323 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 221 | $1,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $228 | $153,747227 claims |
| Astellas Pharma US IncMyrbetriq | $236 | $92,345135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 369 urology providers in Georgia.
Other urology in Savannah
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Scott MillerRoswell$85K
- Matthew SandAtlanta$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.